SACCHETTI, Emilio
 Distribuzione geografica
Continente #
NA - Nord America 13.162
AS - Asia 5.787
EU - Europa 5.380
SA - Sud America 919
Continente sconosciuto - Info sul continente non disponibili 477
AF - Africa 153
OC - Oceania 32
Totale 25.910
Nazione #
US - Stati Uniti d'America 12.929
CN - Cina 2.282
SG - Singapore 1.754
IT - Italia 1.341
UA - Ucraina 1.219
BR - Brasile 765
HK - Hong Kong 669
DE - Germania 645
PL - Polonia 404
GB - Regno Unito 387
FR - Francia 325
FI - Finlandia 318
VN - Vietnam 284
RU - Federazione Russa 242
IN - India 233
TR - Turchia 199
IE - Irlanda 196
CA - Canada 130
BD - Bangladesh 88
SE - Svezia 68
AR - Argentina 62
MX - Messico 52
ZA - Sudafrica 48
NL - Olanda 47
CZ - Repubblica Ceca 45
BE - Belgio 43
JP - Giappone 38
ID - Indonesia 37
SA - Arabia Saudita 32
NG - Nigeria 29
IQ - Iraq 27
ES - Italia 24
AU - Australia 23
EC - Ecuador 23
PK - Pakistan 22
CO - Colombia 19
IR - Iran 19
MA - Marocco 16
UZ - Uzbekistan 16
VE - Venezuela 15
JM - Giamaica 14
EU - Europa 12
LT - Lituania 12
CH - Svizzera 11
KE - Kenya 11
PH - Filippine 11
TH - Thailandia 11
AT - Austria 10
EG - Egitto 10
MU - Mauritius 10
CL - Cile 9
GR - Grecia 9
UY - Uruguay 9
AE - Emirati Arabi Uniti 8
NZ - Nuova Zelanda 8
PY - Paraguay 8
TN - Tunisia 8
TT - Trinidad e Tobago 8
DZ - Algeria 7
PT - Portogallo 7
MY - Malesia 6
PE - Perù 6
AL - Albania 5
IL - Israele 5
JO - Giordania 5
NP - Nepal 5
PS - Palestinian Territory 5
SV - El Salvador 5
BG - Bulgaria 4
BH - Bahrain 4
KR - Corea 4
PA - Panama 4
SI - Slovenia 4
AM - Armenia 3
CI - Costa d'Avorio 3
CR - Costa Rica 3
ET - Etiopia 3
KW - Kuwait 3
LA - Repubblica Popolare Democratica del Laos 3
AG - Antigua e Barbuda 2
AO - Angola 2
BB - Barbados 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
GT - Guatemala 2
HN - Honduras 2
HR - Croazia 2
KG - Kirghizistan 2
LB - Libano 2
LK - Sri Lanka 2
OM - Oman 2
RO - Romania 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BZ - Belize 1
CU - Cuba 1
CW - ???statistics.table.value.countryCode.CW??? 1
Totale 25.424
Città #
Fairfield 1.348
Woodbridge 1.196
Ashburn 1.037
Singapore 951
Jacksonville 896
Houston 820
Hong Kong 666
Ann Arbor 606
Chandler 588
Seattle 536
Cambridge 514
Wilmington 483
Beijing 428
Warsaw 400
San Jose 399
The Dalles 364
Princeton 358
New York 336
Nanjing 320
Council Bluffs 226
Dublin 192
Helsinki 174
Brescia 163
Los Angeles 159
Istanbul 156
Lauterbourg 154
Milan 140
Nanchang 120
Columbus 110
Lancaster 101
Shenyang 101
Des Moines 96
Dearborn 94
Ho Chi Minh City 92
Changsha 90
Dallas 90
Hebei 89
Jinan 86
Moscow 79
Buffalo 77
Munich 77
Tianjin 77
Shanghai 66
Chicago 65
São Paulo 65
Santa Clara 63
San Francisco 61
Redondo Beach 56
Jiaxing 53
San Diego 52
Hanoi 51
Boardman 47
Rome 40
Washington 39
Hangzhou 38
London 38
Ningbo 38
Orem 38
Tokyo 36
Zhengzhou 35
Montreal 33
San Mateo 33
Inzago 32
Phoenix 32
Guangzhou 31
Lanzhou 31
Rio de Janeiro 31
Toronto 31
Frankfurt am Main 30
Abuja 29
Brussels 28
Norwalk 28
Chennai 27
Taizhou 27
Turku 27
Brooklyn 26
Brno 25
Kunming 25
Verona 25
Denver 24
Leawood 24
Romola 24
Atlanta 22
Haikou 21
Johannesburg 21
Mexico City 20
Riyadh 19
Stockholm 19
Augusta 18
Boston 18
Mantova 18
Belo Horizonte 17
Brugherio 17
Taiyuan 17
Mumbai 15
Olomouc 15
Bareggio 14
Berchem 14
Candia 14
Dong Ket 14
Totale 16.806
Nome #
Analysis of DTI brain data and implementation in a novel software (DTILAB) 917
Exome sequencing in schizophrenic patients with high levels of homozygosity identifies novel and extremely rare mutations in the GABA/glutamatergic pathways 327
New Copy Number Variations in Schizophrenia 323
Compound heterozygosity for a large CNV deletion and a rare missense mutation in the FSTL5 gene of a patient affected by schizophrenia. 310
The Effect of Antipsychotic Treatment on Cortical Gray Matter Changes in Schizophrenia: Does the Class Matter? A Meta-analysis and Meta-regression of Longitudinal Magnetic Resonance Imaging Studies 275
Is structured group psychoeducation for bipolar patients effective in ordinary mental health services? A controlled trial in Italy 241
Predictors of cognitive improvement and normalization under cognitive remediation in patients with schizophrenia. 241
Compound heterozygosity for a hemizygous rare missense variant (rs141999351) and a large CNV deletion affecting the FSTL5 gene in a patient with schizophrenia 232
A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: The QUERISOLA trial. 209
A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment. 205
-G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: Meta-analysis plus association study 205
Adult ADHD: Prevalence and Clinical Correlates in a Sample of Italian Psychiatric Outpatients 202
Gene per la neuregulina 1 e schizofrenia: ulteriori evidenze di associazione 195
Association study and mutational screening of SYNGR1 as a candidate susceptibility gene for schizophrenia 189
-G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: Meta-analysis plus association study 189
Interview-based assessment of cognition in schizophrenia: applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care. 188
Combined measure of smooth pursuit eye movements and ventricle-brain ratio in schizophrenic disorders. 187
Comparison of quetiapine, olanzapine and risperidone in schizophrenia. 187
Effectiveness of different modalities of cognitive remediation on symptomatological, neuropsychological, and functional outcome domains in schizophrenia: A prospective study in a real-world setting 186
The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia 186
A STUDY OF EFFECTIVENESS OF STRUCTURED GROUP PSYCHOEDUCATION FOR BIPOLAR PATIENTS. A CONTROLLED TRIAL IN ITALY 186
Psychomotor agitation in subjects hospitalized for an acute exacerbation of Schizophrenia 185
Analysis of Copy Number Variations in Schizophrenia Italian Patients 183
Comparison of Quetiapine, Olanzapine, and Risperidone in Patients With Schizophrenia: Interim Results of a Randomised, Rater-blinded Study. 182
Does cognitive remediation modify the use of psychiatric services and the patterns of care of patients with schizophrenia? 178
Cognitive remediation in schizophrenia. 178
Comparison of quetiapine (‘Seroquel’), olanzapine and risperidone in a randomized study in patients with schizophrenia. 176
A genome-wide pharmacogenomic study of patients with schizophrenia suggests that GRM7 mediates the effects of risperidone on positive symptoms 172
Functional study of a novel homozygous mutation in the GAD1 gene, detected in a patient with schizophrenia. 172
Schizotassia 171
Brain structural abnormalities at the onset of schizophrenia and bipolar disorder: a meta-analysis of controlled magnetic resonance imaging studies 171
Alpha reactivity in schizophrenia and in schizophrenic spectrum disorders: demographic, clinical and hemispheric assessment. 167
The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis 166
At-risk gambling in patients with severe mental illness. Prevalence and associated features. 166
Interim results of a randomised, rater-blinded study comparing quetiapine, olanzapine and risperidone in patients with schizophrenia. 165
Antipsychotics, antidepressants, anticonvulsants, and placebo on symptom dimensions of borderline personality disorder: a meta-analysis of randomized controlled and open-label trials 163
Psychopathologic, neuropsychological and functional outcome measures during cognitive rehabilitation in schizophrenia: A prospective controlled study in a real-world setting. 162
Virological and immunological study of schizophrenic patients in relation to CT scan abnormality. 162
Are SSRI antidepressants a clinically homogeneous class of compounds? 161
Adherence to antipsychotics in schizophrenia. 161
Developmental brain abnormalities in schizophrenia: contributions of genetic and perinatal factors. 160
Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study 160
The role of the cytochine network in schizophrenia: an overview. 160
Well-being in patients with schizophrenia, mood and personality disorders attending psychiatric services in the community. A controlled study 160
Depressive disorders and personality variables in HIV positive and negative intravenous drug-users 159
Cognitive remediation in schizophrenia: a controlled study 158
Persistence of effectiveness of cognitive remediation interventions in schizophrenia: A 1-year follow-up study. 158
Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis 156
The Role of Metabotropic Glutamate Receptor Genes in Schizophrenia 156
A multimodal imaging study of never-medicated adults with schizophrenia 153
Brain morphology in schizophrenic disorder: prevalence and correlates of diffuse (cortical and subcortical) brain atrophy. 152
Deranged anterior pituitary responsiveness to hypothalamic hormones in depressed patients 151
Patterns of Brain Structural Changes in First-Contact, Antipsychotic Drug-Naive Patients with Schizophrenia. 151
Schizophrenia susceptibility and NMDA-receptor mediated signalling: an association study involving 32 tagSNPs of DAO, DAOA, PPP3CC, and DTNBP1 genes. 150
Factors affecting antipsychotic drug discontinuation in the treatment of schizophrenia: Evidence from a naturalistic, retrospective, 18-month follow-up study. 148
Quetiapine in hospitalized patients with schizophrenia refractory to treatment with first-generation antipsychotics: a 4-week, flexible-dose, single-blind, exploratory, pilot trial. 148
Factors related to different reasons for antipsychotic drug discontinuation in the treatment of schizophrenia: A naturalistic 18-month follow-up study. 148
Additional Evidence for White Matter Damage in Never-Medicated Adults with Schizophrenia and Schizophreniform Disorder 148
Exome sequencing of schizophrenia patients with high level of homozygosity identifies a homozygous novel mutation that reduces the glutamate acid decarboxylase 67 (GAD67) activity 148
Season of birth and cerebral ventricular enlargement in schizophrenia 147
Personal resources and depression in schizophrenia: The role of self-esteem, resilience and internalized stigma 147
Self-ordered pointing and visual conditional associative learning tasks in drug-free schizophrenia spectrum disorder patients. 145
Fertility and marital status in mood disorders: relationship with age at onset. 145
Association study between schizophrenia and the AMPA genes GRIA1, GRIA2 AND GRIA4 144
Non pharmacological strategies to enhance adherence and continuity of care in schizophrenia. 144
Post-traumatic stress disorder and subthreshold post-traumatic stress disorder in recent male asylum seekers: An expected but overlooked “European” epidemic 144
Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report. 143
Cytokine profiles in drug-naive schizophrenic patients. 143
CT scan abnormalities and outcome of chronic schizophrenia 143
Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. 143
Gray matter, white matter, brain, and intracranial volumes in first-episode bipolar disorder: a meta-analysis of magnetic resonance imaging studies 143
Study on GRIA2, GRIA3 and GRIA4 genes highlights a positive association between schizophrenia and GRIA3 in female patients 143
Cortical atrophy in schizophrenia: prevalence and associated features 142
Negative symptom severity at discharge from an index hospitalization and subsequent use of psychiatric care resources: A retrospective 1-year follow-up study on 450 patients with schizophrenia spectrum disorders 142
Glutamate AMPA receptor subunit 1 gene (GRIA1) and DSM-IV-TR schizophrenia: a pilot case-control association study in an Italian sample 141
Carlo Lorenzo Cazzullo (1915-2010): father of Italian psychiatry 140
Early life events and affective disorder revisited. 139
Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. 139
Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. 138
La cognitività sociale nella schizofrenia: modelli interpretativi e strategie di intervento 138
Polymorphic CA repeat in IGF-I gene: lack of association with schizophrenia. 136
Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients 136
Detection of high level of autozygosity in a group of Italian schizophrenia patients 135
Change in core symptoms of borderline personality disorder by tDCS: A pilot study 134
Immediate and 8-Month Impact of a Medical Educational Course for General Practitioners on Knowledge About Schizophrenia and Its Treatment: Results of a 3-Phase Study From Brescia, Italy. 133
Incidence of diabetes in a general practice population: a database cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure. 133
Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy. 133
Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review 133
CLINICAL ASSESSMENT OF COGNITIVE IMPAIRMENT IN SCHIZOPHRENIA THROUGH THE SCHIZOPHRENIA COGNITION RATING SCALE: A VALIDATION STUDY IN THE ITALIAN POPULATION 133
Variables Associated With General Practitioners' Knowledge About and Diagnostic Skills for Schizophrenia 132
Cerebrovascular accidents in elderly people treated with antipsychotic drugs. A systematic review 132
Reducing the "revolving door" phenomenon. 131
DIRECT TRANSITION TO LONG-ACTING RISPERIDONE--ANALYSIS OF LONG-TERM EFFICACY. 131
Structural brain abnormalities in bipolar disorder: what meta-analyses tell us 131
Timing of stroke in elderly people exposed to typical and atypical antipsychotics: a replication cohort study after the paper of Kleijer, et al. 131
Whole exome sequencing of schizophrenia patients with high level of autozygosity. 130
Relationship of IQ to neuropsychological tasks involving prefrontal cortex in schizophrenia. 130
Neuromorphological correlates of mood disorders: focus on cerebral ventricular enlargement. 130
H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. 129
The factor structure analysis for the positive and negative syndrome scale (PANSS) in pharmacogenetics and pharmacogenomics studies. 129
Totale 17.180
Categoria #
all - tutte 113.051
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 113.051


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.059 0 0 26 66 32 65 69 90 82 166 132 331
2022/20231.589 218 24 17 163 129 430 1 179 281 17 56 74
2023/20241.464 95 35 115 109 73 376 61 51 277 28 19 225
2024/20252.880 38 39 42 340 361 238 216 95 257 240 613 401
2025/20265.565 663 765 388 829 548 468 759 172 260 499 137 77
2026/2027873 283 291 299 0 0 0 0 0 0 0 0 0
Totale 25.910